NCT02039180 - Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Healthy VolunteersPharmacologic Action

Interventions

DRUG

AZD3293 oral solution

Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.

DRUG

AZD3293 tablet formulation A

Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.

DRUG

AZD3293 tablet formulation B

Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.

Trial Locations (1)

Research Site, Cypress